Manu V Chakravarthy
Overview
Explore the profile of Manu V Chakravarthy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1487
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schneider J, Tozzo E, Chakravarthy M
Front Endocrinol (Lausanne)
. 2022 Aug;
13:944728.
PMID: 35937799
No abstract available.
2.
Harrison S, Baum S, Gunn N, Younes Z, Kohli A, Patil R, et al.
Am J Gastroenterol
. 2021 Aug;
116(12):2399-2409.
PMID: 34382947
Introduction: AXA1125 and AXA1957 are novel, orally administered endogenous metabolic modulator compositions, specifically designed to simultaneously support multiple metabolic and fibroinflammatory pathways associated with nonalcoholic fatty liver disease (NAFLD). This...
3.
Daou N, Viader A, Cokol M, Nitzel A, Chakravarthy M, Afeyan R, et al.
Sci Rep
. 2021 Jun;
11(1):11861.
PMID: 34088912
Nonalcoholic steatohepatitis (NASH) is a complex metabolic disease of heterogeneous and multifactorial pathogenesis that may benefit from coordinated multitargeted interventions. Endogenous metabolic modulators (EMMs) encompass a broad set of molecular...
4.
Dennis A, Kelly M, Fernandes C, Mouchti S, Fallowfield J, Hirschfield G, et al.
Front Endocrinol (Lausanne)
. 2021 Feb;
11:575843.
PMID: 33584535
Introduction: Late stage clinical trials in non-alcoholic steatohepatitis (NASH) are currently required by the FDA to use liver biopsy as a primary endpoint. The well-reported limitations with biopsy, such as...
5.
Chakravarthy M, Siddiqui M, Forsgren M, Sanyal A
Front Endocrinol (Lausanne)
. 2021 Jan;
11:592373.
PMID: 33424768
Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions, affecting an estimated one-quarter of the world's adult population. Multiple organ systems have been implicated in the pathophysiology of NAFLD; however,...
6.
Hamill M, Afeyan R, Chakravarthy M, Tramontin T
iScience
. 2020 Oct;
23(10):101628.
PMID: 33103071
Multifactorial disease pathophysiology is complex and incompletely addressed by existing targeted pharmacotherapies. Amino acids (AAs) and related metabolites and precursors are a class of endogenous metabolic modulators (EMMs) that have...
7.
Chakravarthy M, Neuschwander-Tetri B
Endocrinol Diabetes Metab
. 2020 Oct;
3(4):e00112.
PMID: 33102794
Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease and is associated with significant morbidity and mortality worldwide, with a high incidence in Western countries and...
8.
Chakravarthy M, Neutel J, Confer S, Zhao P, Tatsuta N, Rebello S, et al.
Clin Transl Gastroenterol
. 2020 Sep;
11(8):e00222.
PMID: 32955200
Introduction: AXA1665 is a novel investigational amino acid (AA) composition specifically designed to impact AA imbalance, ammoniagenesis, and dysregulated anabolic activity associated with cirrhosis. Methods: This 2-part study examined AXA1665...
9.
Chakravarthy M, Waddell T, Banerjee R, Guess N
Gastroenterol Clin North Am
. 2020 Feb;
49(1):63-94.
PMID: 32033765
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis are diseases in their own right as well as modifiable risk factors for cardiovascular disease and type 2 diabetes. With expanding knowledge...
10.
Holloway T, McGlory C, McKellar S, Morgan A, Hamill M, Afeyan R, et al.
Front Nutr
. 2019 Jul;
6:105.
PMID: 31355205
Skeletal muscle disuse leads to atrophy, declines in muscle function, and metabolic dysfunction that are often slow to recover. Strategies to mitigate these effects would be clinically relevant. In a...